Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen
- 1 January 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (1) , 47-52
- https://doi.org/10.1097/00002030-200201040-00007
Abstract
To determine the importance of resistance and drug levels in the response to a dual-protease inhibitor (PI) combination. Prospective study of 62 HIV-positive patients who switched to a salvage regimen including nelfinavir plus saquinavir. Virological response was defined as a decrease in viraemia > 0.5 log10 after 24 weeks. Optimal PI levels were defined as those above the protein binding-corrected 95% inhibitory concentration (IC95), as estimated in the presence of 50% human serum. Baseline median HIV load was 4.78 log10 copies/ml. The median number of mutations in the protease gene was nine (range, 2–25), predominantly at residues 82 (52%), and 90 (40%). After 24 weeks, 45% of patients had responded and 19% were P Genotypic resistance predicts the virological response to a nelfinavir–saquinavir salvage regimen. Our data suggest that higher than optimal drug levels could be necessary to control the replication of many PI-resistant viruses.Keywords
This publication has 23 references indexed in Scilit:
- Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic OutcomeThe Journal of Infectious Diseases, 1999
- Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trialAIDS, 1999
- Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individualsAIDS, 1998
- Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failureAIDS, 1998
- The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyAIDS, 1998
- Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patientsAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patientsAIDS, 1997
- Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavirAIDS, 1997
- Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patientsAIDS, 1997